Screenshot of the paragraph from the linked document reading "Ensure foreign nations pay their fair share for American innovation: The United States should leverage the Joint Review to fulfill the objective set forth in Section 3 of President Trump’s May 12, 2025, Executive Order, which directed USTR and DOC to address foreign acts, policies or practices that have “the effect of forcing American patients to pay for a disproportionate amount of global pharmaceutical research and development, including by suppressing the price of pharmaceutical products below fair market value in foreign countries.”7 Despite being one of the world’s most developed economies, Canada employs a range of measures that artificially devalue medical innovations developed in the United States and limit and delay patient access to American-made innovative medicines. As a result, Canada spends only 0.32 percent of its GDP per capita on new innovative medicines, compared to 0.78 percent in the United States.8 USTR should require Canada to adopt binding and enforceable trade commitments to achieve an appropriate level of spending on new innovative medicines." with the last sentence highlighted
In an absolutely shocking turn of events, #PhRMA (Pharmaceutical Research and Manufacturers of America) believes, in their submission to the #USMCA/#CUSMA trade agreement review, that Canada should be paying more for medicines.
🛃💊💰
www.phrma.org/resources/ph...